Zacks: Brokerages Expect G1 Therapeutics Inc (NASDAQ:GTHX) Will Announce Earnings of -$0.97 Per Share

Wall Street analysts expect G1 Therapeutics Inc (NASDAQ:GTHX) to report ($0.97) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.90) and the lowest is ($1.07). G1 Therapeutics reported earnings of ($0.65) per share in the same quarter last year, which indicates a negative year over year growth rate of 49.2%. The business is scheduled to report its next quarterly earnings report on Thursday, February 27th.

On average, analysts expect that G1 Therapeutics will report full-year earnings of ($3.29) per share for the current financial year, with EPS estimates ranging from ($3.39) to ($3.23). For the next financial year, analysts expect that the business will post earnings of ($4.43) per share, with EPS estimates ranging from ($5.34) to ($3.92). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for G1 Therapeutics.

Several research analysts have recently issued reports on GTHX shares. ValuEngine upgraded shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research cut shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 8th. BTIG Research raised their target price on shares of G1 Therapeutics from $51.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and issued a $74.00 price target on shares of G1 Therapeutics in a report on Thursday, December 12th. Finally, Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a report on Thursday, December 12th. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $61.43.

Shares of G1 Therapeutics stock traded down $0.10 on Friday, hitting $19.05. The stock had a trading volume of 188,223 shares, compared to its average volume of 237,397. The company has a quick ratio of 14.28, a current ratio of 14.28 and a debt-to-equity ratio of 0.03. G1 Therapeutics has a one year low of $13.87 and a one year high of $41.80. The stock has a market cap of $719.32 million, a price-to-earnings ratio of -6.41 and a beta of 2.31. The stock’s 50-day simple moving average is $23.42 and its two-hundred day simple moving average is $26.57.

A number of large investors have recently added to or reduced their stakes in GTHX. Rhenman & Partners Asset Management AB boosted its holdings in G1 Therapeutics by 95.3% in the third quarter. Rhenman & Partners Asset Management AB now owns 535,657 shares of the company’s stock valued at $12,202,000 after acquiring an additional 261,383 shares in the last quarter. State Street Corp boosted its holdings in G1 Therapeutics by 19.8% in the fourth quarter. State Street Corp now owns 1,375,328 shares of the company’s stock valued at $36,350,000 after acquiring an additional 227,433 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in G1 Therapeutics in the second quarter valued at $3,505,000. Vanguard Group Inc. boosted its holdings in G1 Therapeutics by 5.4% in the second quarter. Vanguard Group Inc. now owns 1,976,615 shares of the company’s stock valued at $60,603,000 after acquiring an additional 100,523 shares in the last quarter. Finally, Redmile Group LLC boosted its holdings in G1 Therapeutics by 33.5% in the third quarter. Redmile Group LLC now owns 390,934 shares of the company’s stock valued at $8,905,000 after acquiring an additional 98,200 shares in the last quarter. Institutional investors and hedge funds own 76.68% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Recommended Story: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.